Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Di...(erior to aflibercept uncertainty of mark...),Health

Date:9/11/2009

erior to aflibercept, uncertainty of market acceptance of aflibercept, the potential for any collaboration agreement, including Regeneron's agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or to terminate without any product success, risks associated with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2008 and Form 10-Q for the quarter ending June 30, 2009. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.

    Contacts

    Regeneron:
    Peter Dworkin
    Investor Relations
    914.345.7640
    peter.dworkin@regeneron.com
    or
    Laura Lindsay
    Media Relations
    914.345.7800
    laura.lindsay@regeneron.com

    sanofi-aventis:
    Sebastien Martel
    Investor Relations
    +33 1 53 77 45 43
    sebastien.martel@sanofi-aventis.com
    or
    Salah Mahyaoui
    Media Relations
    +33 1 53 77 40 31
    salah.mahyaoui@sanofi-aventis.com

'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.; sanofi-aventis Copyright©2009 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
2. Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes
3. MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
4. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
5. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
6. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
7. Hoviones TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
8. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
9. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
10. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA
11. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials